Crossmark

A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors

Crossref DOI link: https://doi.org/10.1007/s00280-018-3619-3

Published Online: 2018-06-09

Published Print: 2018-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sehdev, Amikar

Karrison, Theodore

Zha, Yuanyuan

Janisch, Linda

Turcich, Michelle

Cohen, Ezra E. W.

Maitland, Michael

Polite, Blase N.

Gajewski, Thomas F.

Salgia, Ravi

Pinto, Navin

Bissonnette, Marc B.

Fleming, Gini F.

Ratain, Mark J.

Sharma, Manish R.
Funding

Funding for this research was provided by:

Comprehensive Cancer Center, University of Chicago (P30CA014599)

Comprehensive Cancer Center, University of Chicago (P30CA014599)
License Information

Text and Data Mining valid from 2018-06-09
More Information

Article History

Received: 15 May 2018

Accepted: 4 June 2018

First Online: 9 June 2018

Compliance with ethical standards

:

: Dr. Ratain has provided expert testimony on behalf of generic drug companies regarding the everolimus patents.